



GNI Announces Management Change

Tokyo, December 21, 2007 – GNI Ltd, a leading biopharmaceutical company in Japan and China, announced that Christopher J. Savoie, Ph.D., resigned as its Chairman and President, effective as of December 21, 2007. Dr. Savoie also resigned his positions as Representative Director and as a member of the Board of Directors. Dr. Savoie will remain as an adviser to the Board of Directors. Kanichiro Suzuki, GNI's CFO, was named as a Representative Director and President.

“I am very proud of our many achievements over the past six years, including being selected as one of the top growing companies in Asia by Deloitte and culminating with our initial public offering earlier this year”, stated Dr. Savoie. I will continue to help GNI to move forward to become a major pharmaceutical company in Japan and China.”

“We are very grateful for Christopher’s leadership. Our initial public offering was an important milestone for us, and we wish to acknowledge Christopher’s role in this achievement.” added Mr. Suzuki. Mr. Suzuki continued, “We also recently implemented an Executive Committee to manage the day-to-day operations. The new management team has been working hard to consolidate our operations in both Japan and China, as evidenced by our steady progress in clinical trials, research and business development.”

GNI Ltd. also announced that Taketoshi Kobayashi has joined the company as an adviser. Mr. Kobayashi is formerly a Representative Director and Vice President of Nippon Boehringer Ingelheim Co., Ltd.

Ying Luo, Ph.D., Chief Executive Officer of GNI, Ltd., stated, “Mr. Kobayashi provides us with tremendous knowledge on the global pharmaceutical market, and also valuable operational experience. He will help us to strengthen our management capability. We are confident that Mr. Kobayashi’s presence will be a great asset for our future growth.”

About GNI

Founded in 2001, GNI is a clinical-stage international drug development company with its headquarters in Japan and major operations in China. GNI has successfully mapped gene regulatory networks via a complex process of reverse-engineering. Furthermore, GNI has developed technology to apply this data to drug development and discovery. In June 2005, GNI acquired Shanghai Genomics, which operates an integrated drug discovery and development platform in Shanghai, China. The combined strength of GNI and Shanghai Genomics has resulted in research collaborations with major international pharmaceutical companies. For further information, please visit www.gene-networks.com and www.shanghaigenomics.com.